United States Multivalent Vaccines Market Report & Forecast 2021-2027

Publisher Name :
Date: 11-Oct-2021
No. of pages: 108
Inquire Before Buying

United States Multivalent Vaccines Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (K Pcs)

United States Multivalent Vaccines Market Segment Percentages, By Type, 2020 (%)

- Conjugate Vaccines

- Inactivated and Subunit Vaccines

- Live Attenuated Vaccines

- Toxoid Vaccines

- Recombinant Vaccines

United States Multivalent Vaccines Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (K Pcs)

United States Multivalent Vaccines Market Segment Percentages, By Application, 2020 (%)

- Pediatrics

- Adults

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Multivalent Vaccines revenues in United States market, 2016-2021 (Estimated), ($ millions)

Key companies Multivalent Vaccines revenues share in United States market, 2020 (%)

Key companies Multivalent Vaccines sales in United States market, 2016-2021 (Estimated), (K Pcs)

Key companies Multivalent Vaccines sales share in United States market, 2020 (%)

Further, the report presents profiles of competitors in the market, key players include:

- GlaxoSmithKline, plc (U.K.)

- Pfizer, Inc (US)

- Merck & Co., Inc (US)

- Sanofi Pasteur SA (France)

- Astellas Pharma Inc. (Japan)

- CSL Limited (Australia)

- Emergent BioSolutions, Inc (US)

- Johnson & Johnson (US)

- MedImmune, LLC (US)

- Serum Institute of India Pvt. Ltd. (India)

- Bavarian Nordic (Denmark)

- Mitsubishi Tanabe Pharma Corporation (Japan)

- Daiichi Sankyo (Japan)

- Protein Sciences Corporation (US)

- Panacea Biotec (India)

United States Multivalent Vaccines Market Report & Forecast 2021-2027

Table of Contents
1 Introduction to Research & Analysis Reports
1.1 Multivalent Vaccines Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 United States Multivalent Vaccines Market Overview
1.4 Methodology & Sources of Information
1.4.1 Research Methodology
1.4.2 Research Process
1.4.3 Base Year
2 United States Multivalent Vaccines Overall Market Size
2.1 United States Multivalent Vaccines Market Size: 2021 VS 2027
2.2 United States Multivalent Vaccines Revenue, Prospects & Forecasts: 2016-2027
2.3 United States Multivalent Vaccines Sales: 2016-2027
3 Company Landscape
3.1 Top Multivalent Vaccines Players in United States Market
3.2 Top United States Multivalent Vaccines Companies Ranked by Revenue
3.3 United States Multivalent Vaccines Revenue by Companies
3.4 United States Multivalent Vaccines Sales by Companies
3.5 United States Multivalent Vaccines Price by Manufacturer (2016-2021)
3.6 Top 3 and Top 5 Multivalent Vaccines Companies in United States Market, by Revenue in 2020
3.7 Manufacturers Multivalent Vaccines Product Type
3.8 Tier 1, Tier 2 and Tier 3 Multivalent Vaccines Players in United States Market
3.8.1 List of Tier 1 Multivalent Vaccines Companies in United States
3.8.2 List of Tier 2 and Tier 3 Multivalent Vaccines Companies in United States
4 Sights by Type
4.1 Overview
4.1.1 By Type - United States Multivalent Vaccines Market Size Markets, 2021 & 2027
4.1.2 Conjugate Vaccines
4.1.3 Inactivated and Subunit Vaccines
4.1.4 Live Attenuated Vaccines
4.1.5 Toxoid Vaccines
4.1.6 Recombinant Vaccines
4.2 By Type - United States Multivalent Vaccines Revenue & Forecasts
4.2.1 By Type - United States Multivalent Vaccines Revenue, 2016-2021
4.2.2 By Type - United States Multivalent Vaccines Revenue, 2022-2027
4.2.3 By Type - United States Multivalent Vaccines Revenue Market Share, 2016-2027
4.3 By Type - United States Multivalent Vaccines Sales & Forecasts
4.3.1 By Type - United States Multivalent Vaccines Sales, 2016-2021
4.3.2 By Type - United States Multivalent Vaccines Sales, 2022-2027
4.3.3 By Type - United States Multivalent Vaccines Sales Market Share, 2016-2027
4.4 By Type - United States Multivalent Vaccines Price (Manufacturers Selling Prices), 2016-2027
5 Sights by Application
5.1 Overview
5.1.1 By Application - United States Multivalent Vaccines Market Size, 2021 & 2027
5.1.2 Pediatrics
5.1.3 Adults
5.2 By Application - United States Multivalent Vaccines Revenue & Forecasts
5.2.1 By Application - United States Multivalent Vaccines Revenue, 2016-2021
5.2.2 By Application - United States Multivalent Vaccines Revenue, 2022-2027
5.2.3 By Application - United States Multivalent Vaccines Revenue Market Share, 2016-2027
5.3 By Application - United States Multivalent Vaccines Sales & Forecasts
5.3.1 By Application - United States Multivalent Vaccines Sales, 2016-2021
5.3.2 By Application - United States Multivalent Vaccines Sales, 2022-2027
5.3.3 By Application - United States Multivalent Vaccines Sales Market Share, 2016-2027
5.4 By Application - United States Multivalent Vaccines Price (Manufacturers Selling Prices), 2016-2027
6 Manufacturers & Brands Profiles
6.1 GlaxoSmithKline, plc (U.K.)
6.1.1 GlaxoSmithKline, plc (U.K.) Corporation Information
6.1.2 GlaxoSmithKline, plc (U.K.) Overview
6.1.3 GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Sales and Revenue in United States Market (2016-2021)
6.1.4 GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Product Description
6.1.5 GlaxoSmithKline, plc (U.K.) Recent Developments
6.2 Pfizer, Inc (US)
6.2.1 Pfizer, Inc (US) Corporation Information
6.2.2 Pfizer, Inc (US) Overview
6.2.3 Pfizer, Inc (US) Multivalent Vaccines Sales and Revenue in United States Market (2016-2021)
6.2.4 Pfizer, Inc (US) Multivalent Vaccines Product Description
6.2.5 Pfizer, Inc (US) Recent Developments
6.3 Merck & Co., Inc (US)
6.3.1 Merck & Co., Inc (US) Corporation Information
6.3.2 Merck & Co., Inc (US) Overview
6.3.3 Merck & Co., Inc (US) Multivalent Vaccines Sales and Revenue in United States Market (2016-2021)
6.3.4 Merck & Co., Inc (US) Multivalent Vaccines Product Description
6.3.5 Merck & Co., Inc (US) Recent Developments
6.4 Sanofi Pasteur SA (France)
6.4.1 Sanofi Pasteur SA (France) Corporation Information
6.4.2 Sanofi Pasteur SA (France) Overview
6.4.3 Sanofi Pasteur SA (France) Multivalent Vaccines Sales and Revenue in United States Market (2016-2021)
6.4.4 Sanofi Pasteur SA (France) Multivalent Vaccines Product Description
6.4.5 Sanofi Pasteur SA (France) Recent Developments
6.5 Astellas Pharma Inc. (Japan)
6.5.1 Astellas Pharma Inc. (Japan) Corporation Information
6.5.2 Astellas Pharma Inc. (Japan) Overview
6.5.3 Astellas Pharma Inc. (Japan) Multivalent Vaccines Sales and Revenue in United States Market (2016-2021)
6.5.4 Astellas Pharma Inc. (Japan) Multivalent Vaccines Product Description
6.5.5 Astellas Pharma Inc. (Japan) Recent Developments
6.6 CSL Limited (Australia)
6.6.1 CSL Limited (Australia) Corporation Information
6.6.2 CSL Limited (Australia) Overview
6.6.3 CSL Limited (Australia) Multivalent Vaccines Sales and Revenue in United States Market (2016-2021)
6.6.4 CSL Limited (Australia) Multivalent Vaccines Product Description
6.6.5 CSL Limited (Australia) Recent Developments
6.7 Emergent BioSolutions, Inc (US)
6.7.1 Emergent BioSolutions, Inc (US) Corporation Information
6.7.2 Emergent BioSolutions, Inc (US) Overview
6.7.3 Emergent BioSolutions, Inc (US) Multivalent Vaccines Sales and Revenue in United States Market (2016-2021)
6.7.4 Emergent BioSolutions, Inc (US) Multivalent Vaccines Product Description
6.7.5 Emergent BioSolutions, Inc (US) Recent Developments
6.8 Johnson & Johnson (US)
6.8.1 Johnson & Johnson (US) Corporation Information
6.8.2 Johnson & Johnson (US) Overview
6.8.3 Johnson & Johnson (US) Multivalent Vaccines Sales and Revenue in United States Market (2016-2021)
6.8.4 Johnson & Johnson (US) Multivalent Vaccines Product Description
6.8.5 Johnson & Johnson (US) Recent Developments
6.9 MedImmune, LLC (US)
6.9.1 MedImmune, LLC (US) Corporation Information
6.9.2 MedImmune, LLC (US) Overview
6.9.3 MedImmune, LLC (US) Multivalent Vaccines Sales and Revenue in United States Market (2016-2021)
6.9.4 MedImmune, LLC (US) Multivalent Vaccines Product Description
6.9.5 MedImmune, LLC (US) Recent Developments
6.10 Serum Institute of India Pvt. Ltd. (India)
6.10.1 Serum Institute of India Pvt. Ltd. (India) Corporation Information
6.10.2 Serum Institute of India Pvt. Ltd. (India) Overview
6.10.3 Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Sales and Revenue in United States Market (2016-2021)
6.10.4 Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Product Description
6.10.5 Serum Institute of India Pvt. Ltd. (India) Recent Developments
6.11 Bavarian Nordic (Denmark)
6.11.1 Bavarian Nordic (Denmark) Corporation Information
6.11.2 Bavarian Nordic (Denmark) Overview
6.11.3 Bavarian Nordic (Denmark) Multivalent Vaccines Sales and Revenue in United States Market (2016-2021)
6.11.4 Bavarian Nordic (Denmark) Multivalent Vaccines Product Description
6.11.5 Bavarian Nordic (Denmark) Recent Developments
6.12 Mitsubishi Tanabe Pharma Corporation (Japan)
6.12.1 Mitsubishi Tanabe Pharma Corporation (Japan) Corporation Information
6.12.2 Mitsubishi Tanabe Pharma Corporation (Japan) Overview
6.12.3 Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Sales and Revenue in United States Market (2016-2021)
6.12.4 Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Product Description
6.12.5 Mitsubishi Tanabe Pharma Corporation (Japan) Recent Developments
6.13 Daiichi Sankyo (Japan)
6.13.1 Daiichi Sankyo (Japan) Corporation Information
6.13.2 Daiichi Sankyo (Japan) Overview
6.13.3 Daiichi Sankyo (Japan) Multivalent Vaccines Sales and Revenue in United States Market (2016-2021)
6.13.4 Daiichi Sankyo (Japan) Multivalent Vaccines Product Description
6.13.5 Daiichi Sankyo (Japan) Recent Developments
6.14 Protein Sciences Corporation (US)
6.14.1 Protein Sciences Corporation (US) Corporation Information
6.14.2 Protein Sciences Corporation (US) Overview
6.14.3 Protein Sciences Corporation (US) Multivalent Vaccines Sales and Revenue in United States Market (2016-2021)
6.14.4 Protein Sciences Corporation (US) Multivalent Vaccines Product Description
6.14.5 Protein Sciences Corporation (US) Recent Developments
6.15 Panacea Biotec (India)
6.15.1 Panacea Biotec (India) Corporation Information
6.15.2 Panacea Biotec (India) Overview
6.15.3 Panacea Biotec (India) Multivalent Vaccines Sales and Revenue in United States Market (2016-2021)
6.15.4 Panacea Biotec (India) Multivalent Vaccines Product Description
6.15.5 Panacea Biotec (India) Recent Developments
7 United States Multivalent Vaccines Production Capacity, Analysis
7.1 United States Multivalent Vaccines Production Capacity, 2016-2027
7.2 Multivalent Vaccines Production Capacity of Key Manufacturers in United States Market
8 Key Market Trends, Opportunity, Drivers and Restraints
8.1 Market Opportunities & Trends
8.2 Market Drivers
8.3 Market Restraints
9 Multivalent Vaccines Supply Chain Analysis
9.1 Multivalent Vaccines Industry Value Chain
9.2 Multivalent Vaccines Upstream Market
9.3 Multivalent Vaccines Downstream and Clients
9.4 Marketing Channels Analysis
9.4.1 Marketing Channels
9.4.2 Multivalent Vaccines Distributors and Sales Agents in United States Market
10 Conclusion
11 Appendix
11.1 Note
11.2 Examples of Clients
11.3 Author Details
11.4 Disclaimer
List of Tables
Table 1. Key Players of Multivalent Vaccines in United States Market
Table 2. Top Multivalent Vaccines Players in United States Market, Ranking by Revenue (2019)
Table 3. United States Multivalent Vaccines Revenue by Companies, (US$, Mn), 2016-2021
Table 4. United States Multivalent Vaccines Revenue Share by Companies, 2016-2021
Table 5. United States Multivalent Vaccines Sales by Companies, (K Pcs), 2016-2021
Table 6. United States Multivalent Vaccines Sales Share by Companies, 2016-2021
Table 7. Key Manufacturers Multivalent Vaccines Price (2016-2021) & (USD/Pcs)
Table 8. Manufacturers Multivalent Vaccines Product Type
Table 9. List of Tier 1 Multivalent Vaccines Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Tier 2 and Tier 3 Multivalent Vaccines Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. Major Manufacturers of Conjugate Vaccines
Table 12. Major Manufacturers of Inactivated and Subunit Vaccines
Table 13. By Type - United States Multivalent Vaccines Revenue, (US$, Mn), 2021 & 2027
Table 14. By Type - United States Multivalent Vaccines Revenue (US$, Mn), 2016-2021
Table 15. By Type - United States Multivalent Vaccines Revenue (US$, Mn), 2022-2027
Table 16. By Type - United States Multivalent Vaccines Sales (K Pcs), 2016-2021
Table 17. By Type - United States Multivalent Vaccines Sales (K Pcs), 2022-2027
Table 18. By Application - United States Multivalent Vaccines Revenue, (US$, Mn), 2021 VS 2027
Table 19. By Application - United States Multivalent Vaccines Revenue (US$, Mn), 2016-2021
Table 20. By Application - United States Multivalent Vaccines Revenue (US$, Mn), 2022-2027
Table 21. By Application - United States Multivalent Vaccines Sales (K Pcs), 2016-2021
Table 22. By Application - United States Multivalent Vaccines Sales (K Pcs), 2022-2027
Table 23. GlaxoSmithKline, plc (U.K.) Corporation Information
Table 24. GlaxoSmithKline, plc (U.K.) Description and Major Businesses
Table 25. GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Gross Margin (USD/Pcs) (2016-2021)
Table 26. GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Product
Table 27. GlaxoSmithKline, plc (U.K.) Recent Developments
Table 28. Pfizer, Inc (US) Corporation Information
Table 29. Pfizer, Inc (US) Description and Major Businesses
Table 30. Pfizer, Inc (US) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Gross Margin (USD/Pcs) (2016-2021)
Table 31. Pfizer, Inc (US) Multivalent Vaccines Product
Table 32. Pfizer, Inc (US) Recent Developments
Table 33. Merck & Co., Inc (US) Corporation Information
Table 34. Merck & Co., Inc (US) Description and Major Businesses
Table 35. Merck & Co., Inc (US) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Gross Margin (USD/Pcs) (2016-2021)
Table 36. Merck & Co., Inc (US) Multivalent Vaccines Product
Table 37. Merck & Co., Inc (US) Recent Developments
Table 38. Sanofi Pasteur SA (France) Corporation Information
Table 39. Sanofi Pasteur SA (France) Description and Major Businesses
Table 40. Sanofi Pasteur SA (France) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Gross Margin (USD/Pcs) (2016-2021)
Table 41. Sanofi Pasteur SA (France) Multivalent Vaccines Product
Table 42. Sanofi Pasteur SA (France) Recent Developments
Table 43. Astellas Pharma Inc. (Japan) Corporation Information
Table 44. Astellas Pharma Inc. (Japan) Description and Major Businesses
Table 45. Astellas Pharma Inc. (Japan) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Gross Margin (USD/Pcs) (2016-2021)
Table 46. Astellas Pharma Inc. (Japan) Multivalent Vaccines Product
Table 47. Astellas Pharma Inc. (Japan) Recent Developments
Table 48. CSL Limited (Australia) Corporation Information
Table 49. CSL Limited (Australia) Description and Major Businesses
Table 50. CSL Limited (Australia) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Gross Margin (USD/Pcs) (2016-2021)
Table 51. CSL Limited (Australia) Multivalent Vaccines Product
Table 52. CSL Limited (Australia) Recent Developments
Table 53. Emergent BioSolutions, Inc (US) Corporation Information
Table 54. Emergent BioSolutions, Inc (US) Description and Major Businesses
Table 55. Emergent BioSolutions, Inc (US) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Gross Margin (USD/Pcs) (2016-2021)
Table 56. Emergent BioSolutions, Inc (US) Multivalent Vaccines Product
Table 57. Emergent BioSolutions, Inc (US) Recent Developments
Table 58. Johnson & Johnson (US) Corporation Information
Table 59. Johnson & Johnson (US) Description and Major Businesses
Table 60. Johnson & Johnson (US) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Gross Margin (USD/Pcs) (2016-2021)
Table 61. Johnson & Johnson (US) Multivalent Vaccines Product
Table 62. Johnson & Johnson (US) Recent Developments
Table 63. MedImmune, LLC (US) Corporation Information
Table 64. MedImmune, LLC (US) Description and Major Businesses
Table 65. MedImmune, LLC (US) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Gross Margin (USD/Pcs) (2016-2021)
Table 66. MedImmune, LLC (US) Multivalent Vaccines Product
Table 67. MedImmune, LLC (US) Recent Developments
Table 68. Serum Institute of India Pvt. Ltd. (India) Corporation Information
Table 69. Serum Institute of India Pvt. Ltd. (India) Description and Major Businesses
Table 70. Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Gross Margin (USD/Pcs) (2016-2021)
Table 71. Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Product
Table 72. Serum Institute of India Pvt. Ltd. (India) Recent Developments
Table 73. Bavarian Nordic (Denmark) Corporation Information
Table 74. Bavarian Nordic (Denmark) Description and Major Businesses
Table 75. Bavarian Nordic (Denmark) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Gross Margin (USD/Pcs) (2016-2021)
Table 76. Bavarian Nordic (Denmark) Multivalent Vaccines Product
Table 77. Bavarian Nordic (Denmark) Recent Developments
Table 78. Mitsubishi Tanabe Pharma Corporation (Japan) Corporation Information
Table 79. Mitsubishi Tanabe Pharma Corporation (Japan) Description and Major Businesses
Table 80. Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Gross Margin (USD/Pcs) (2016-2021)
Table 81. Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Product
Table 82. Mitsubishi Tanabe Pharma Corporation (Japan) Recent Developments
Table 83. Daiichi Sankyo (Japan) Corporation Information
Table 84. Daiichi Sankyo (Japan) Description and Major Businesses
Table 85. Daiichi Sankyo (Japan) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Gross Margin (USD/Pcs) (2016-2021)
Table 86. Daiichi Sankyo (Japan) Multivalent Vaccines Product
Table 87. Daiichi Sankyo (Japan) Recent Developments
Table 88. Protein Sciences Corporation (US) Corporation Information
Table 89. Protein Sciences Corporation (US) Description and Major Businesses
Table 90. Protein Sciences Corporation (US) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Gross Margin (USD/Pcs) (2016-2021)
Table 91. Protein Sciences Corporation (US) Multivalent Vaccines Product
Table 92. Protein Sciences Corporation (US) Recent Developments
Table 93. Panacea Biotec (India) Corporation Information
Table 94. Panacea Biotec (India) Description and Major Businesses
Table 95. Panacea Biotec (India) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Gross Margin (USD/Pcs) (2016-2021)
Table 96. Panacea Biotec (India) Multivalent Vaccines Product
Table 97. Panacea Biotec (India) Recent Developments
Table 98. Multivalent Vaccines Production Capacity (K Pcs) of Key Manufacturers in United States Market, 2019-2021 (K Pcs)
Table 99. United States Multivalent Vaccines Capacity Market Share of Key Manufacturers, 2019-2021
Table 100. Multivalent Vaccines Market Opportunities & Trends in United States Market
Table 101. Multivalent Vaccines Market Drivers in United States Market
Table 102. Multivalent Vaccines Market Restraints in United States Market
Table 103. Multivalent Vaccines Raw Materials
Table 104. Multivalent Vaccines Raw Materials Suppliers in United States Market
Table 105. Typical Multivalent Vaccines Downstream
Table 106. Multivalent Vaccines Downstream Clients in United States Market
Table 107. Multivalent Vaccines Distributors and Sales Agents in United States Market
List of Figures
Figure 1. Multivalent Vaccines Product Picture
Figure 2. Multivalent Vaccines Segment by Type
Figure 3. Multivalent Vaccines Segment by Application
Figure 4. United States Multivalent Vaccines Market Overview: 2020
Figure 5. United States Multivalent Vaccines Market Size: 2021 VS 2027 (US$, Mn)
Figure 6. United States Multivalent Vaccines Revenue, 2016-2027 (US$, Mn)
Figure 7. Multivalent Vaccines Sales in United States Market: 2016-2027 (K Pcs)
Figure 8. The Top 3 and 5 Players Market Share by Multivalent Vaccines Revenue in 2020
Figure 9. Conjugate Vaccines Product Picture
Figure 10. Inactivated and Subunit Vaccines Product Picture
Figure 11. Live Attenuated Vaccines Product Picture
Figure 12. Toxoid Vaccines Product Picture
Figure 13. Recombinant Vaccines Product Picture
Figure 14. By Type - United States Multivalent Vaccines Sales Market Share, 2016-2027
Figure 15. By Type - United States Multivalent Vaccines Revenue Market Share, 2016-2027
Figure 16. By Type - United States Multivalent Vaccines Price (USD/Pcs), 2016-2027
Figure 17. Pediatrics
Figure 18. Adults
Figure 19. By Application - United States Multivalent Vaccines Sales Market Share, 2016-2027
Figure 20. By Application - United States Multivalent Vaccines Revenue Market Share, 2016-2027
Figure 21. By Application - United States Multivalent Vaccines Price (USD/Pcs), 2016-2027
Figure 22. GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 23. Pfizer, Inc (US) Multivalent Vaccines Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 24. Merck & Co., Inc (US) Multivalent Vaccines Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 25. Sanofi Pasteur SA (France) Multivalent Vaccines Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 26. Astellas Pharma Inc. (Japan) Multivalent Vaccines Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 27. CSL Limited (Australia) Multivalent Vaccines Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 28. Emergent BioSolutions, Inc (US) Multivalent Vaccines Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 29. Johnson & Johnson (US) Multivalent Vaccines Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 30. MedImmune, LLC (US) Multivalent Vaccines Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 31. Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 32. Bavarian Nordic (Denmark) Multivalent Vaccines Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 33. Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 34. Daiichi Sankyo (Japan) Multivalent Vaccines Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 35. Protein Sciences Corporation (US) Multivalent Vaccines Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 36. Panacea Biotec (India) Multivalent Vaccines Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 37. United States Multivalent Vaccines Production Capacity (K Pcs), 2016-2027
Figure 38. Multivalent Vaccines Industry Value Chain
Figure 39. Marketing Channels
  • China Ocular Drug Delivery Market Report & Forecast 2021-2027
    Published: 26-Oct-2021        Price: US 3400 Onwards        Pages: 91
    China Ocular Drug Delivery Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (K Doses) China Ocular Drug Delivery Market Segment Percentages, By Type, 2020 (%) - Ocular Insert - Iontophoresis - Intraocular Implants - In Situ Gel & Punctal Plugs - Others China Ocular Drug Delivery Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (K Doses) China Ocular Drug Delivery Market Segment Percentages, By Application, 2020 (%)......
  • China Nuclear Medicine/Radiopharmaceutic Market Report & Forecast 2021-2027
    Published: 26-Oct-2021        Price: US 3400 Onwards        Pages: 93
    China Nuclear Medicine/Radiopharmaceutic Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (Kiloton) China Nuclear Medicine/Radiopharmaceutic Market Segment Percentages, By Type, 2020 (%) - Tc-99 - I-123/131 - In-111 - Xe-133 - Th-201 - Ga-67 - Other China Nuclear Medicine/Radiopharmaceutic Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (Kiloton) China Nuclear Medicine/Radiopharmaceutic Market Segment P......
  • China NSAIDs Market Report & Forecast 2021-2027
    Published: 26-Oct-2021        Price: US 3400 Onwards        Pages: 90
    China NSAIDs Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (K Pcs) China NSAIDs Market Segment Percentages, By Type, 2020 (%) - Aspirin - Ibuprofen - Naproxen - Nabumetone - Others China NSAIDs Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (K Pcs) China NSAIDs Market Segment Percentages, By Application, 2020 (%) - Back Pain Treatment - Osteoarthritis Treatment - Other Disease Treatment......
  • China Non-Tyrosine Kinase Inhibitors Market Report & Forecast 2021-2027
    Published: 26-Oct-2021        Price: US 3400 Onwards        Pages: 107
    China Non-Tyrosine Kinase Inhibitors Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (K Pcs) China Non-Tyrosine Kinase Inhibitors Market Segment Percentages, By Type, 2020 (%) - mTOR Inhibitors - RAF/MEK Inhibitors - CDK Inhibitors China Non-Tyrosine Kinase Inhibitors Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (K Pcs) China Non-Tyrosine Kinase Inhibitors Market Segment Percentages, By Application, 2020 (%) - Liver Can......
  • China Nonsteroidal Antiinflammatory Drugs Market Report & Forecast 2021-2027
    Published: 26-Oct-2021        Price: US 3400 Onwards        Pages: 90
    China Nonsteroidal Antiinflammatory Drugs Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (K Pcs) China Nonsteroidal Antiinflammatory Drugs Market Segment Percentages, By Type, 2020 (%) - Oral Nonsteroidal Antiinflammatory Drugs - Injection Nonsteroidal Antiinflammatory Drugs China Nonsteroidal Antiinflammatory Drugs Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (K Pcs) China Nonsteroidal Antiinflammatory Drugs Market Segment Percenta......
  • China Non-opioid Pain Patch Market Report & Forecast 2021-2027
    Published: 26-Oct-2021        Price: US 3400 Onwards        Pages: 107
    China Non-opioid Pain Patch Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (M Units) China Non-opioid Pain Patch Market Segment Percentages, By Type, 2020 (%) - Lidocaine Patches - Diclofenac Patches - Indomethacin Patches - Counter-Irritant Patches - Fentanyl Patches - Others China Non-opioid Pain Patch Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (M Units) China Non-opioid Pain Patch Market Segment Perc......
  • China Non Narcotic Analgesics Market Report & Forecast 2021-2027
    Published: 26-Oct-2021        Price: US 3400 Onwards        Pages: 92
    China Non Narcotic Analgesics Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (K Pcs) China Non Narcotic Analgesics Market Segment Percentages, By Type, 2020 (%) - Non Steroid Antiinflammatory Drug - Steroid Antiinflammatory Drug China Non Narcotic Analgesics Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (K Pcs) China Non Narcotic Analgesics Market Segment Percentages, By Application, 2020 (%) - Hospital - Medical Center......
  • Global Azelastine Nasal Spray Market Research Report 2021
    Published: 26-Oct-2021        Price: US 2900 Onwards        Pages: 100
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - 0.137MG/SPRAY - 0.2055MG/SPRAY - Other Segment by Application - Hospital - Ret......
  • Global Azelastine Drug Market Research Report 2021
    Published: 26-Oct-2021        Price: US 2900 Onwards        Pages: 114
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Nasal Spray - Eye Drops - Other Segment by Application - Hospital - Retail Pha......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs